A topical treatment combining calcipotriol and 5-FU shows promise in reducing premalignant lesions and lowering skin cancer risk by activating Th2 immunity.

Discover how a new study highlights the transformative potential of Th2 immunity in early cancer intervention.

Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not ...